The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection

• Status: Recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Growing evidence of Tranexamic Acid (TXA) being used to reduce blood loss and blood transfusions in various guidelines. However, the adverse effects of TXA especially seizure has always been a problem of concern, especially in neurosurgery. Therefore, this study aims to provide a scientific evidence for the safety of TXA in supratentorial meningiomas resection patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• 1) age 18-80 years

• 2) American Society of Anesthesiologist (ASA) classification score I~III

Exclusion Criteria:

• 1) allergic to tranexamic acid

• 2) preoperative seizures

• 3) history of thrombotic disease

• 4) chronic kidney disease

• 5) breastfeeding or pregnancy

• 6) refuse to participate in the study